Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2207-2210

  Zahreddine, Hiba Ahmad ^a   Borden, Katherine L B ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE B17; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; GLI1 PROTEIN, HUMAN; GLUCURONIC ACID; TRANSCRIPTION FACTOR;

ALTERNATIVE RNA SPLICING; ARTICLE; DNA DAMAGE; DNA METHYLATION; DOWN REGULATION; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; ANIMAL; DRUG INACTIVATION; ENZYMOLOGY; GLYCOSYLATION; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; GLYCOSYLATION; HUMANS; INACTIVATION, METABOLIC; NEOPLASMS; TRANSCRIPTION FACTORS; ZINC FINGER PROTEIN GLI1;

EID: 84941985486     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1370     Document Type: Article

References (20)

1. Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013;4:28.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2: 48-58.
3. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 2014; 511:90-3.
4. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009;114: 257-60.
5. Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, et al. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica 2015;100:e7-9.
6. Dutton GJ. Glucuronidation of drugs and other compounds. Boca Raton (FL): CRC Press; 1980.
7. Guillemette C, Levesque E, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther 2014;96:324-39.
8. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40: 581-616.
9. Burchell B. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am J Pharmacogenomics 2003;3:37-52.
10. Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood 2013;121: 1175-83.
11. Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Beißbarth T, et al. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell Death Dis 2014;5:e1411.
12. Belange AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol Biol 2010;11:9.
13. Oda S, Fukami T, Yokoi T, Nakajima M. Epigenetic regulation of the tissuespecific expression of human UDP-glucuronosyltransferase (UGT) 1A10. Biochem Pharmacol 2014;87:660-7.
14. Rieger JK, Klein K, Winter S, Zanger UM. Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression. Drug Metab Dispos 2013;41:1752-62.
15. Yokoi T, Nakajima M. microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 2013;53:377-400.
16. Girard H, Lévesque E, Bellemare J, Journault K, Caillier B, Guillemette C. Genetic diversity at the UGT1 locus is amplified by a novel 3′ alternative splicingmechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics 2007; 17:1077-89.
17. Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Têtu B, et al. Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans. J Pathol 2011;223:425-35.
18. Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013;45:1121-32.
19. Kutsuno Y, Sumida K, Itoh T, Tukey RH, Fujiwara R. Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: similarity with glucuronidation in human liver microsomes. Pharmacol Res Perspect 2013;1:e00002.
20. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med 2014;11:e1001628.